Benzinga | Jun 8, 2021 07:08AM EDT

Anavex Life Sciences Announces Exceeding Of Enrollment Target For Precision Medicine ANAVEX2-73 Phase 2b/3 Clinical Trial in Patients With Alzheimer's Disease

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it has exceeded its enrollment target for the ANAVEX(r)2-73 (blarcamesine) Phase 2b/3 study in Alzheimer's disease. The Company expects to announce topline results from this study by mid-2022.